<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401530</url>
  </required_header>
  <id_info>
    <org_study_id>E7777-J081-101</org_study_id>
    <nct_id>NCT01401530</nct_id>
  </id_info>
  <brief_title>E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma</brief_title>
  <official_title>Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1 study is to determine the maximum tolerated dose (MTD) through
      observation of dose limiting toxicity (DLT), which is in advance defined, in patients with
      peripheral or cutaneous T-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>3 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>E7777</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denileukin diftitox (E7777)</intervention_name>
    <description>E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.</description>
    <arm_group_label>E7777</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        lnclusion Criteria:

          -  Male and female patients 20 to less than 80 years of age at the time of informed
             consent

          -  Patients histologically or cytologically diagnosed to have peripheral T -cell lymphoma

          -  Patients with a history of chemotherapy (including PUVA and retinoid) that resulted in
             relapse, recurrence and treatment resistance (just for the administration of E7777
             alone)

          -  Patients subject to CHOP therapy and without a history of prior treatment with
             anthracycline or anthraquinone anticancer drugs (just for the administration of E7777
             in combination with CHOP therapy)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  No carry-over of beneficial or adverse effects of the prior treatment that may affect
             the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and
             alopecia)

        Exclusion Criteria:

        Brain metastasis with clinical symptoms which requires treatment

        Serious systemic infection requiring intensive treatment

        Serious complications or histories

        History of hypersensitivity to protein therapeutics

        Known to be positive for HIV antibody, HCV antibody, or HBs antigen

        History of malignancy other than peripheral T-cell lymphoma and less than five years have
        elapsed since the last remission

        Patients who have undergone allogeneic hematopoietic stem cell transplantation

        Patients with a relapse within 6 months after autologous hematopoietic stem-cell
        transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tadashi Nakanishi</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2011</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin</keyword>
  <keyword>T- Cell</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>lmmune System Diseases</keyword>
  <keyword>lmmunoproliferative Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 22, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

